About this episode
When Covid-19 hit, Gilead Sciences Inc. had enough of its experimental drug remdesivir ready to test and start manufacturing it at a larger scale. That's because it had started stockpiling not just the drug, but its ingredients, at the first hint there may be a new coronavirus. Robert Langreth reports on why the company was able to act early to prepare for a pandemic when so many businesses and institutions did not.
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time Prognosis: Misconception publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Prognosis: Misconception
Introducing: Levittown
Prognosis: Misconception
Listen Now: Beak Capitalism from Odd Lots
Prognosis: Misconception
Misconception: Great Expectations
Prognosis: Misconception
Misconception: Big Baby
Prognosis: Misconception